CIBMTR Research Database

Recruiting

• Conditions: Solid Tumors; Blood Cancers; Gene Therapy; Non-malignant Disease; Autologous Stem Cell Transplantation; Allogeneic Stem Cell Transplantation; CAR-T

• Registration Number: NCT01166009
• Lead Sponsor: Center for International Blood and Marrow Transplant Research

Brief Summary

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.

A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries.

Objectives:

To learn more about what makes stem cell transplants and cellular therapies work well such as:

* Determine how well recipients recover from their transplants or cellular therapy;

* Determine how recovery after a transplant or cellular therapy can be improved;

* Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy;

* Determine how access to transplant or cellular therapy for different groups of patients can be improved;

* Determine how well donors recover from the collection procedures.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-07
• Study First Submitted: 2010-07-16
• Study First Submitted QC: 2010-07-19
• Study First Posted: 2010-07-20
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-29
• Last Update Posted: 2025-01-31
• Primary Completion: 2025-07
• Study Completion: 2030-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 99999999

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A Comprehensive Source of Observational Data to assess Stem Cell Transplant	Anually - on average	A primary outcome is to have a comprehensive source of stem cell transplant data that can be used to assess topics such as: * Recipient Recover time; * How recovery after transplant and other cellular therapies can be improved; * Long term outcomes after transplantation and other cellular therapies; * How well donors recover from collection procedure

Secondary Outcome Measures

Name	Time	Method
A Comprehensive Source of Data for Marrow Toxic Injuries	anually- on average	In the event of a radiation exposure accident, the NMDP has a radiation injury treatment network, whose purpose is to collect data to understand the outcomes of patients treated under these circumstances. Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Database.
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (10CMSMDS-1)	annually - on average	This protocol supports data collection for a sub-study titled 10-CMSMDS-1 with objective to prospectively examine outcomes of allogenic hematopoietic cell transplant in adults \>= 65 years of age with myelodysplastic syndrome to determine whether their outcomes are similar to those in younger patients.; * To provide a mechanism for Medicare Beneficiaries with myelodysplastic syndrome for claims coverage for allogenic hematopoietic cell transplant; * To provide data requested by Medicare under its CED to make payment on claims for HCT using the existing research observational database of the CIBMTR"
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (17-CMS-SCD)	annually - on average	This protocol supports data collection for a sub study titled 17-CMS-SCD, an observational study to compare survival of patients 15 to 50 years of age with sickle cell disease who receive allogeneic transplantation compared to those receiving standard of care treatments.; * To provide a mechanism to Medicare Beneficiaries with sickle cell disease for claims coverage for allogenic hematopoietic cell transplant.; * To provide data requested by Medicare under its coverage with evidence development (CED) process to make payment on claims for HCT using the existing research observational database for the CIBMTR

Trial Locations

Locations (2)

Center for International Blood and Marrow Transplant Research; 🇺🇸 Minneapolis, Minnesota, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States